Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377491 · ClinicalTrials.gov registry record · Phase 3
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
A Phase 3 study, sponsored by NovoCure.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
NCT03377491 is a Phase 3 study that has completed, run by NovoCure. The registered enrollment target is 571 participants.
The verdict
NCT03377491, a Phase 3 study, has completed, sponsored by NovoCure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
Study Summary
Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Interventions
- DRUG Gemcitabine
- DEVICE NovoTTF-200T
- DRUG nab paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03377491
The ClinicalTrials.gov registry entry for NCT03377491 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03377491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03377491 about?
NCT03377491 is a clinical study titled "Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)". Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an expe...
What is the current status of trial NCT03377491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2018-05-10. Estimated completion is 2024-10-16.
What interventions are being tested in trial NCT03377491?
The interventions under investigation include: Gemcitabine (DRUG), NovoTTF-200T (DEVICE), nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03377491?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.